Send to

Choose Destination
J Pediatr Pharmacol Ther. 2014 Jan;19(1):42-8. doi: 10.5863/1551-6776-19.1.42.

Parenteral nutrition-associated liver disease: a retrospective study of ursodeoxycholic Acid use in neonates.

Author information

Department of Pharmacy, CHU Sainte-Justine, Montreal, Canada.
Department of Pharmacy, CHU Sainte-Justine, Montreal, Canada ; Faculty of Pharmacy, University of Montreal, Montreal, Canada.
Faculty of Medicine, University of Montreal, Montreal, Canada.



To verify the effect of ursodeoxycholic acid (UDCA) on the duration of neonatal parenteral nutrition-associated liver disease.


Retrospective cohort study of neonates in intensive care between 2004 and 2007 presenting with parenteral nutrition-associated liver disease.


Of 118 eligible infants, 64 received UDCA. Cholestasis lasted longer in the UDCA group (79 vs. 50 days, p=0.001). However, treatment was delayed for a median of 24 days after cholestasis onset. Multivariate Cox regression analysis showed no association between UDCA and cholestasis duration. The rate of decline of conjugated bilirubin was greater in treated patients (median 0.084 mg/dL/day vs. 0.60 mg/dL/day; p=0.009) and weight gain was greater (22.8 vs. 17.7 g/kg/day, p=0.010).


UDCA therapy was not associated with the duration of parenteral nutrition-associated liver disease. A delay in treatment initiation might explain this result. UDCA therapy was associated with a faster decline of conjugated bilirubin and greater weight gain.


hyperbilirubinemia; infant; liver disease; neonate; parenteral nutrition; premature; ursodeoxycholic acid

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center